# Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer Patients

> **NCT03895762** · — · COMPLETED · sponsor: **A.Menarini Asia-Pacific Holdings Pte Ltd** · enrollment: 143 (actual)

## Conditions studied

- Breakthrough Cancer Pain

## Interventions

- **DRUG:** Abstral Oral Disintegrating Tablet (ODT)

## Key facts

- **NCT ID:** NCT03895762
- **Lead sponsor:** A.Menarini Asia-Pacific Holdings Pte Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-04
- **Primary completion:** 2019-06-28
- **Final completion:** 2019-06-28
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2022-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03895762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03895762, "Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer Patients". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03895762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*